Enobosarm

Enobosarm (also known as Ostarine, MK-2866, or GTx-024) is a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar anabolic properties to anabolic steroids but with reduced androgenic properties. Enobosarm is designed to selectively bind to androgen receptors in muscle and bone tissue, promoting muscle growth and bone density without the significant side effects associated with traditional steroids, such as prostate enlargement or virilization in women.

Enobosarm was initially developed for the treatment of muscle wasting conditions, such as sarcopenia and cachexia, as well as for osteoporosis. Its anabolic effects have also led to its use and misuse as a performance-enhancing drug in sports.

However, it is important to note that Enobosarm is not approved for human use by regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its sale and use are often prohibited or restricted, particularly in competitive sports. The World Anti-Doping Agency (WADA) has banned its use by athletes.

Potential side effects, though generally considered less severe than those of anabolic steroids, are still under investigation and may include, but are not limited to, hormonal imbalances, changes in cholesterol levels, and potential long-term health risks. Due to the lack of comprehensive research and regulatory approval, the safety and efficacy of Enobosarm remain a concern.